Telix Pharmaceuticals boss Christian Behrenbruch says it was "worrisome" that he had to weigh up the escalating political tensions with Beijing when penning the radiation oncology company's $450 million deal with one of China's largest pharma companies.
Telix is a late-stage biotech looking to potentially diagnose and treat various forms of prostate, kidney and brain cancer by developing radiopharmaceutical theranostics (combinations of diagnostics and therapeutics).
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
